Floatz logo

Tak-228

Recurrent Adult Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

74 Active assets in the Recurrent Adult Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB

View all 50 →

Same molecule, other indications

Tak-228 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Recurrent Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
pancreatic neuroendocrine tumorDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →